Federal Register / Vol. 65, No. 15 / Monday, January 24, 2000 / Notices 3717

California, and First Community Bank

of the Desert, Indian Wells, California.

2. First Community Bancorp, Rancho

Santa Fe, California; to become a bank

holding company by acquiring 100

percent of the voting shares of Rancho

Santa Fe National Bank, Rancho Santa

Fe, California, and First Community

Bank of the Desert, Indian Wells,

California.

Board of Governors of the Federal Reserve

System, January 18, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00–1576 Filed 1–21–00; 8:45 am]

BILLING CODE 6210–01–P

FEDERAL TRADE COMMISSION

Revised Jurisdictional Thresholds for

Section 8 of the Clayton Act

AGENCY: Federal Trade Commission.

ACTION: Notice.

SUMMARY: The Federal Trade

Commission announces the revised

thresholds for interlocking directorates

required by the 1990 amendment of

section 8 of the Clayton Act. Section 8

prohibits, with certain exceptions, one

person from serving as a director or

officer of two competing corporations if

two thresholds are met. Competitor

corporations are covered by section 8 if

each one has capital, surplus, and

undivided profits aggregating more than

$10,000,000, with the exception that no

corporation is covered if the competitive

sales of either corporation are less than

$1,000,000. Section 8(a)(5) requires the

Federal Trade Commission to revise

those thresholds annually, based on the

change in gross national product. The

new thresholds, which take effect

immediately, are $16,732,000 for section

8(a)(1), and $1,673,200 for section

8(a)(2)(A).

EFFECTIVE DATE: January 24, 2000.

FOR FURTHER INFORMATION CONTACT: H.

Gabriel Dagen, Bureau of Competition,

Office of Accounting and Financial

Analysis, (202) 326–2573.

Authority: 15 U.S.C. 19(a)(5).

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 00–1653 Filed 1–21–00; 8:45am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that

the Office of Research Integrity (ORI)

has made a final finding of scientific

misconduct in the following case:

John L. Ho, M.D., Cornell University:

Based on a report dated June 16, 1999,

by Cornell University (Report), as well

as information obtained by ORI during

its oversight review, ORI found that Dr.

John Ho, Associate Professor,

Department of Medicine and

Department of Microbiology at Cornell

University Medical College, engaged in

scientific misconduct by reporting

falsified and fabricated research results

in a National Heart, Lung, and Blood

Institute (NHLBI), National Institutes of

Health (NIH), grant application.

Specifically, ORI found that Dr. John

Ho committed scientific misconduct in

connection with the data contained in

Figure 10 of the Application that

purportedly demonstrated cytokine

production heterogeneity. Dr. John Ho

falsified the text describing Panel 2 of

Figure 10 by representing that the

interferon-γ values reflected data from

25 donors when values from only four

donors had been obtained. In addition,

Dr. John Ho falsified the data entries for

Panels 1 and 3 of Figure 10 by

representing that approximately 19 and

25 donor samples, respectively, were

studied when only three and six

genuine values were obtained, the

remaining symbols reflecting fabricated

results.

Dr. John Ho has accepted the ORI

finding and has entered into a Voluntary

Exclusion Agreement with ORI in which

he has voluntarily agreed:

(1) to comply with all terms and

conditions of the plan for remedial

training and scientific and

administrative oversight imposed by

Cornell University. Pursuant to the

Cornell Plan, Dr. John Ho can return to

work at Cornell University only after it

receives written confirmation from Dr.

David Ho that Dr. John Ho has

successfully completed a program of

remedial training of at least one (1)

year’s duration at the Aaron Diamond

Foundation. Under the terms of the

Cornell Plan, Dr. John Ho will be subject

to a two (2) year plan of scientific and

administrative oversight of his research

upon his return to Cornell University

from the Aaron Diamond Foundation.

(2) that, for a period of three (3) years

beginning on December 28, 1999, any

institution (including but not limited to

Cornell University and the Aaron

Diamond Foundation) that submits an

application for U.S. Public Health

Service (PHS) support for a research

project on which Dr. John Ho’s

participation is proposed or which uses

him in any capacity on PHS supported

research, or that submits a report of

PHS-funded research in which he is

involved, must concurrently submit to

PHS and ORI:

a. a plan for supervision of his duties

during the particular PHS-related

project at issue, which must be designed

to ensure the scientific integrity of his

research contribution; and

b. a certification that the data

provided by Dr. John Ho are based on

actual experiments or are otherwise

legitimately derived, and that the data,

procedures, and methodology are

accurately reported in the application or

research report.

(3) to exclude himself from serving in

any advisory capacity to PHS, including

but not limited to service on any PHS

advisory committee, board, and/or peer

review committee, or as a consultant for

a three (3) year period beginning

December 28, 1999.

Further, in the event that Dr. John Ho

obtains a new employer at anytime

during the three (3) year period

beginning on December 28, 1999, Dr.

John Ho has agreed to:

(1) notify ORI in writing no later than

ten (10) business days after the

commencement of his new employment

of the name and address of his new

employer;

(2) provide his new employer with a

copy of the Agreement (including the

Cornell Plan); and

(3) ensure that, for so long as the

Cornell Plan is in effect, his new

employer will agree to assume the

scientific and research oversight

responsibilities adopted by Cornell

University pursuant to paragraphs 1, 2,

and 3 of the Cornell Plan.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research

Investigations, Office of Research

Integrity, 5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 00–1621 Filed 1–21–00; 8:45 am]

BILLING CODE 4160–17–P